Edition:
India

Catalyst Pharmaceuticals Inc (CPRX.OQ)

CPRX.OQ on NASDAQ Stock Exchange Capital Market

3.36USD
12 Aug 2020
Change (% chg)

-- (--)
Prev Close
$3.36
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
537,521
52-wk High
$7.67
52-wk Low
$2.55

Latest Key Developments (Source: Significant Developments)

Catalyst Pharma Sees FY 2020 Revenue $135 Mln To $155 Mln
Wednesday, 8 Apr 2020 

April 8 (Reuters) - Catalyst Pharmaceuticals Inc ::SEES FY 2020 REVENUE $135 MILLION TO $155 MILLION.DRUG SUPPLY REMAINS WELL-STOCKED WITH PATIENTS HAVING ACCESS TO UNINTERRUPTED SUPPLY OF FIRDAPSE (AMIFAMPRIDINE) 10MG.FIRDAPSE SUPPLY CHAIN REMAINS ROBUST AND READY FOR ANY CONTINGENCIES THAT ARISE DUE TO COVID-19 OUTBREAK.WE HAVE OBSERVED NO DISRUPTIONS IN PRODUCTION OF FIRDAPSE.CONTINUE TO ASSESS POTENTIAL IMPACT THAT COVID-19 COULD HAVE ON OUR REVENUE.REPORTED IT HAD $94.5 MILLION OF CASH AND INVESTMENTS AS OF DECEMBER 31, 2019.AS OF TODAY, CATALYST CONTINUES TO HAVE NO FUNDED DEBT.  Full Article

Catalyst Pharmaceuticals Comments On Trading In Its Stock & On Its Capital Resources
Tuesday, 24 Sep 2019 

Sept 23 (Reuters) - Catalyst Pharmaceuticals Inc ::CATALYST PHARMACEUTICALS, INC. COMMENTS ON TRADING IN ITS COMMON STOCK AND ON ITS CAPITAL RESOURCES.CATALYST PHARMACEUTICALS INC - BELIEVES THAT ITS STOCK REMAINS UNDERVALUED.CATALYST PHARMACEUTICALS INC - DOES NOT BELIEVE RAISING ADDITIONAL CAPITAL IN PUBLIC MARKET IN FORESEEABLE FUTURE WOULD BE IN BEST INTEREST.CATALYST PHARMA - NOT AWARE OF INFORMATION ABOUT CO'S ACTIVITIES THAT HAS NOT BEEN REPORTED THAT WOULD GIVE RISE TO TODAY'S DECLINE IN MARKET PRICE.CATALYST - IF DEAL OR IN-LICENSING OPPORTUNITY WERE TO BE IDENTIFIED, EXPECTS WOULD BE ABLE TO RAISE FUNDS USING NON-DILUTIVE DEBT FINANCING SOURCES.  Full Article

Catalyst Pharmaceuticals Announces Proposed Public Offering Of Common Stock
Thursday, 12 Sep 2019 

Sept 11 (Reuters) - Catalyst Pharmaceuticals Inc ::CATALYST PHARMACEUTICALS, INC. ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.SAYS OFFERING 8.00 MILLION COMMON SHARES.SAYS OFFERING 8.00 MILLION COMMON SHARES.ALL OF SHARES IN OFFERING ARE BEING SOLD BY CATALYST.PLANS TO USE NET PROCEEDS FROM OFFERING TO CONTINUE COMMERCIALIZATION ACTIVITIES FOR FIRDAPSE.PLANS TO ALSO USE NET PROCEEDS FROM OFFERING TO FUND BUSINESS EXPANSION ACTIVITIES IN U.S. AND JAPAN.  Full Article

Catalyst Pharmaceuticals Q2 Earnings Per Share $0.10
Thursday, 8 Aug 2019 

Catalyst Pharmaceuticals Inc ::CATALYST PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q2 EARNINGS PER SHARE $0.10.Q2 EARNINGS PER SHARE ESTIMATE $0.03 -- REFINITIV IBES DATA.ENDED JUNE 30, 2019 WITH $64.9 MILLION IN CASH AND INVESTMENTS AND NO FUNDED DEBT.CATALYST PHARMACEUTICALS - BELIEVES EXISTING CAPITAL RESOURCES WILL BE SUFFICIENT TO SUPPORT ITS PLANNED OPERATIONS FOR AT LEAST NEXT 12 MONTHS.PRODUCT REVENUE, NET IN Q2 2019 WAS $28.8 MILLION.  Full Article

Catalyst Pharmaceuticals Files Federal Lawsuit Against U.S. Food And Drug Administration
Wednesday, 12 Jun 2019 

June 12 (Reuters) - Catalyst Pharmaceuticals Inc ::CATALYST PHARMACEUTICALS FILES FEDERAL LAWSUIT AGAINST U.S. FOOD AND DRUG ADMINISTRATION.CATALYST - LAWSUIT CHALLENGING RECENT APPROVAL OF NDA AND RELATED DRUG LABELING FOR JACOBUS PHARMACEUTICAL COMPANY'S DRUG RUZURGI.CATALYST PHARMACEUTICALS INC - COMPLAINT WAS FILED IN U.S. DISTRICT COURT FOR SOUTHERN DISTRICT OF FLORIDA.CATALYST PHARMACEUTICALS INC - AMONG OTHER REMEDIES, SUIT SEEKS AN ORDER VACATING FDA'S APPROVAL OF RUZURGI.  Full Article

Catalyst Pharmaceuticals Announces Expansion Of Firdapse License To Include Japan
Thursday, 30 May 2019 

May 30 (Reuters) - Catalyst Pharmaceuticals Inc ::CATALYST PHARMACEUTICALS ANNOUNCES EXPANSION OF FIRDAPSE LICENSE TO INCLUDE JAPAN.CATALYST PHARMACEUTICALS INC - WILL PAY ROYALTIES OF A SIMILAR PERCENTAGE OF ITS NET REVENUES DERIVED IN JAPAN AS IN ITS ORIGINAL LICENSE AGREEMENT..CATALYST PHARMACEUTICALS- UPON ACHIEVEMENT OF CERTAIN MILESTONE IN JAPAN, CO TO HAVE OPTION TO EXPAND TO INCLUDE MOST OF ASIA, CENTRAL & SOUTH AMERICA.  Full Article

Catalyst Pharmaceuticals Reports Q1 Results
Monday, 13 May 2019 

May 13 (Reuters) - Catalyst Pharmaceuticals Inc ::CATALYST PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q1 LOSS PER SHARE $0.01.Q1 EARNINGS PER SHARE ESTIMATE $-0.13 -- REFINITIV IBES DATA.AT MARCH 31, 2019, CATALYST HAD CASH AND CASH EQUIVALENTS AND INVESTMENTS OF $50.6 MILLION AND NO FUNDED-DEBT.CONTINUE TO MAKE PROGRESS IN CLINICAL DEVELOPMENT OF PIPELINE OF OTHER POTENTIAL INDICATIONS FOR FIRDAPSE.TOTAL NET REVENUE IN Q1 2019 WAS $12.4 MILLION..TOTAL NET REVENUE IN Q1 2019 WAS $12.4 MILLION.  Full Article

Catalyst Pharmaceuticals Says Qtrly Loss Per Share $0.14
Tuesday, 19 Mar 2019 

March 18 (Reuters) - Catalyst Pharmaceuticals Inc ::CATALYST PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND YEAR-END 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q4 GAAP LOSS PER SHARE $0.14.Q4 EARNINGS PER SHARE ESTIMATE $-0.12 -- REFINITIV IBES DATA.AT DECEMBER 31, 2018, CATALYST HAD CASH AND INVESTMENTS OF $58.5 MILLION AND NO DEBT.  Full Article

Catalyst Pharmaceuticals Announces Definitive Agreement With Endo For Vigabatrin Tablets
Tuesday, 18 Dec 2018 

Catalyst Pharmaceuticals Inc ::CATALYST PHARMACEUTICALS ANNOUNCES DEFINITIVE AGREEMENT WITH ENDO FOR VIGABATRIN TABLETS.CATALYST PHARMACEUTICALS INC - WILL RECEIVE AN UP-FRONT PAYMENT, MILESTONE PAYMENTS BASED ON ACHIEVEMENT OF REGULATORY APPROVALS.CATALYST PHARMACEUTICALS INC - UNDER DEAL, CO TO ALSO RECEIVE SHARING OF DEFINED NET PROFITS UPON COMMERCIALIZATION.CATALYST PHARMACEUTICALS - SIGNED AGREEMENT WITH ENDO INTERNATIONAL'S UNIT FOR FURTHER DEVELOPMENT,COMMERCIALIZATION OF GENERIC SABRIL TABLETS.  Full Article

FDA Grants Approval Of Firdapse To Catalyst Pharmaceuticals
Thursday, 29 Nov 2018 

Nov 28 (Reuters) - U.S. Food and Drug Administration::FDA APPROVES FIRST TREATMENT FOR LAMBERT-EATON MYASTHENIC SYNDROME, A RARE AUTOIMMUNE DISORDER.FDA SAYS GRANTED APPROVAL OF FIRDAPSE TO CATALYST PHARMACEUTICALS INC.  Full Article

BRIEF-Catalyst Pharma Sees FY 2020 Revenue $135 Mln To $155 Mln

* DRUG SUPPLY REMAINS WELL-STOCKED WITH PATIENTS HAVING ACCESS TO UNINTERRUPTED SUPPLY OF FIRDAPSE (AMIFAMPRIDINE) 10MG